Moderna and Merck have reported positive results from a late-stage clinical trial for their mRNA-based cancer vaccine, specifically targeting melanoma treatment.
Following the announcement, Moderna's stock experienced significant volatility, reflecting investor optimism about the potential for this 'game-changer' technology in oncology.
The companies are now preparing for further regulatory reviews, aiming to integrate this vaccine into standard treatment protocols for skin cancer patients.